? CORE A The administrative core for Center for Precision Medicine in Leukemia is co-led by the Co-principal investigators for this P50, Drs. Relling and Loh. The executive committee also includes Dr. Evans, Dr. Hunger, and Dr. Cheng. This is an interdisciplinary group of experienced basic, translational, and clinical investigators who have a proven track record of working together and meeting deadlines. They will work together to oversee the progress on all three projects and two cores to ensure that the Center?s milestones are set and met, and to facilitate interactions between the Center and external groups. The PI and Co-PI (Relling and Loh) are supported by administrative staff at SJCRH. The P50 Administrator, Dawn Bowen, has considerable experience in cancer center and grants administration.
The Specific Aims of this essential core are: (1) To oversee, monitor, and prioritize internal progress of projects, cores and programs to ensure the Center is meetings its milestones. (2) To facilitate internal interactions among Center projects and cores. (3) To facilitate external outreach of the Center to the Pharmacogenomics Research Network (PGRN), the genomics community, the pediatric and adult ALL cooperative groups and other ALL clinical consortia, and the external genomics groups performing clinical implementation of pharmacogenomics and precision medicine. (4) To execute changes in emphasis and direction and devise contingency plans based on changing priorities over time. (5) To ensure outreach to, appointment of, interface with, response to, and planning of meetings with the External Advisory Board (EAB). (6) To coordinate Executive Committee conference calls, monthly web-based Center Work in Progress seminars, EAB interactions, and the annual Center Retreat. (7) To take a leadership role in the PGRN and program and organize a meeting of the PGRN. (8)To ensure timely data sharing and data deposits. (9) To manage budgetary issues and prepare progress reports.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Specialized Center (P50)
Project #
1P50GM115279-01
Application #
8933499
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Zhang, Yingchi; Gao, Yufeng; Zhang, Hui et al. (2018) PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood 131:2256-2261
Gupta, Sumit; Devidas, Meenakshi; Loh, Mignon L et al. (2018) Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). Leukemia 32:1370-1379
Steeghs, Elisabeth M P; Bakker, Marjolein; Hoogkamer, Alex Q et al. (2018) High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia. Sci Rep 8:693
Diouf, Barthelemy; Lin, Wenwei; Goktug, Asli et al. (2018) Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. SLAS Discov 23:164-173
Pui, Ching-Hon (2018) To delay or not to delay, that is the question for patients with acute lymphoblastic leukemia who do not receive prophylactic cranial irradiation. Cancer 124:4442-4446
Churchman, Michelle L; Qian, Maoxiang; Te Kronnie, Geertruy et al. (2018) Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell 33:937-948.e8
Browne, Emily K; Zhou, Yinmei; Chemaitilly, Wassim et al. (2018) Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia. Cancer 124:4248-4259
Diouf, Barthelemy; Evans, William E (2018) Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues. Clin Pharmacol Ther :
Robinson, Katherine M; Yang, Wenjian; Haidar, Cyrine E et al. (2018) Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics J :
Green, Daniel M; Wang, Mingjuan; Krasin, Matthew J et al. (2018) Serum ALT elevations in survivors of childhood cancer. A report from the St. Jude Lifetime Cohort Study. Hepatology :

Showing the most recent 10 out of 72 publications